BioSpace News Archive

Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing, global, dialysis market today announced publication of a multicenter, prospective, open-label study in Hemodialysis International.

OSE Immunotherapeutics, announced a new licensing deal with Chong Kun Dang Pharmaceutical Corporation for Tedopi®, a combination of neoepitopes selected and optimized from five tumor antigens shown to generate a specific response of cytotoxic T cells versus cancer cells expressing at least one of these tumor associated antigens and an associated T-helper cell response, for potential registration and commercialization in Korea.

Eli Lilly and Company announced the pricing terms of its previously announced cash tender offer for up to $2,000,006,000 aggregate principal amount of its outstanding debt securities.

Primary human liver and kidney cells provide important translational research tools for drug discovery and toxicity testing to support innovations in patient care

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, reported business and financial results as of and for the quarter ended September 30, 2019 and provided a corporate update.

Company announces the appointment of Sandra Gardiner as Chief Financial Officer

TearLab Corporation reported its consolidated financial results for the third quarter ended September 30, 2019.

Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, reported financial results for the three months ended September 30, 2019.

Aduro Biotech, Inc. provided a business update and reported financial results for the third quarter ended September 30, 2019.

Implemented restructuring to focus resources primarily on the development of cobomarsen and microRNA-29 mimics, including remlarsen